SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update
Company announced completed Phase 1 enrollment for SAB-142 with no observation of…
Tevogen Bio CEO Dr. Ryan Saadi Expresses Gratitude for Prestigious ROI-NJ Recognition, Highlighting Companys Novel Business Model as Key to Sustainable Success through Patient Affordability
Tevogen Bio is a fully functional biotech, with investor-valued assets over $10…
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
November 03, 2024 16:00 ET | Source: Belite Bio, Inc SAN DIEGO,…